Maze Therapeutics, Inc.

As the son of two scientists, Kevin Parker, 31, never wanted to be a scientist. “I did not grow up thinking that I wanted to be a scientist,” he said. “Both of my parents are PhDs in organic chemistry

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a